Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people
07/05/2025 13:37
May 7 (Reuters) - The European Union's health regulator said on Wednesday it has begun a review of Valneva's VLS.PA chikungunya vaccine after reports of serious adverse events in older adults, including two deaths globally. (Reporting by Mariam Sunny in Bengaluru; Editing by Tasim Zahid) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency